Company: TELO
Filing Date: 2025-11-20
Form Type: PREM14A
Source: 0001493152-25-024463
Chunk: 77

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-20
Form: PREM14A
Chunk 77
---
 for breast cancer at USD 45.5 billion and a forecast to around USD 128.9 billion by 2030. [Insights 10]

Middle East & Africa: In the United Arab Emirates, Breast cancer represents 20% of all malignant cases and 9.6% of cancer-related deaths (Al-Awadhi et al., 2024). NCDs account for 80% of morbidity and 65% of mortality, costing the UAE economy AED 40 billion annually, equivalent to 2.7% of GDP (UAE PHC Costing Report, 2023). National investments in oncology and precision medicine position the UAE as an emerging hub for advanced therapeutics.

Drivers of increased treatment demand

Several factors are converging globally to raise demand for breast cancer treatment:

| ● | Rising                                                                                               
 incidence and prevalence: With more women being diagnosed (and surviving longer), the need           
 for treatment rises.                                                                                 |
| ● | Ageing                                                                                               
 populations: As many countries’ populations age, breast cancer — which increases                     
 with age — becomes more common.                                                                      |
| ● | Improved                                                                                             
 detection and awareness: Greater screening and awareness mean more cases detected (including         
 earlier), which leads to more treatment need.                                                        |
| ● | Expansion                                                                                            
 of treatment options: The growing availability of targeted therapies, biologics, and immunotherapies 
 means more patients are eligible for (and demand) more advanced treatments. For example,             
 reports show increased adoption of biosimilars and targeted drugs in Asia-Pacific. [Global           
 Growth Insights]                                                                                     |
| ● | Healthcare                                                                                           
 infrastructure investments: In many emerging markets, governments and private sectors are            
 building up oncology services, which in turn increases capacity to treat more patients and           
 thus increases demand.                                                                               |

| 44 |

Implications for healthcare systems and market opportunity

From the demand side, here are several implications:

Market growth potential: For pharmaceutical companies, device makers, and diagnostics firms, non-U.S. markets represent major growth opportunities. The forecasted rapid growth in Asia-Pacific, Latin America, and even Middle East/Africa underscores this.

Need for tailored solutions: Because of resource constraints, demand in many countries is for cost-effective therapies, diagnostics, and delivery models (for example, simplified screening, low-cost treatment regimens, task-shifting models).

Health system strengthening: The increasing demand for breast cancer treatment places pressure on health systems outside the U.S., including needs for workforce training (on